1425. Population pharmacokinetic analysis of ciprofloxacin and levofloxacin in critically ill trauma, surgical, and burn patients
Session: Poster Abstract Session: PK/PD Studies
Friday, October 5, 2018
Room: S Poster Hall
Background: Antibiotic pharmacokinetics (PK) differ between critically ill and non-critically ill patients, as do the bacteria causing infection, yet dosing regimens are derived from non-critically ill populations. The purpose of this study was to examine the adequacy of ciprofloxacin and levofloxacin dosing in critically ill trauma, surgery, and burn patients for treating common nosocomial pathogens.

Methods: Time-concentration curves derived from plasma samples in critically ill patients receiving ciprofloxacin 400mg IV q12h (N=11) or q8h (N=5) or levofloxacin 750mg IV q24h (N=9) were used to calculate individual PK parameters and create population PK models. Monte Carlo simulations were performed to assess the cumulative fraction of response (CFR) to achieve the target pharmacodynamic index (PDI) of AUC:MIC ≥ 125, using gram-negative MIC distributions from the European Committee on Antimicrobial Susceptibility Testing.

Results: The fit of both the ciprofloxacin and levofloxacin population models was improved with the addition of CrCl as a covariate. Despite simulating higher dosing regimens, such as ciprofloxacin 600mg q8h and 800mg q8h and levofloxacin 1125mg q24h and 1500mg q24h, only a single dosing regimen/gram-negative species combination demonstrated a CFR ≥90%. This result was consistent with the finding that the maximum MICs at which individual patients achieved the target PDI were well below the CLSI breakpoints of ciprofloxacin and levofloxacin for Enterobacteriaceae, Pseudomonas, and Acinetobacter of ≤1 mg/mL and ≤2 mg/mL, respectively.

Conclusion: In critically ill trauma, surgical, and burn patients, standard dosing regimens of ciprofloxacin and levofloxacin failed to achieve PDIs sufficient to treat optimally Enterobacteriaceae, Pseudomonas, and Acinetobacter isolates with MICs up to the CLSI breakpoints. When increased doses were simulated, the CFR of all but one dose/species combination remained suboptimal. Individualized dosing guided by therapeutic drug monitoring may be an appropriate next step to improve fluoroquinolone efficacy in these critically ill patients.

Kelly Ivins-O'Keefe, BA (MD anticipated May 2018)1,2, Kevin S. Akers, MD, FIDSA1,2,3 and Taylor Schlotman, PhD1, (1)US Army Institute of Surgical Research, JBSA Ft Sam Houston, TX, (2)Uniformed Services University of the Health Sciences, Bethesda, MD, (3)Infectious Disease Service, San Antonio Military Medical Center, Fort Sam Houston, TX

Disclosures:

K. Ivins-O'Keefe, None

K. S. Akers, None

T. Schlotman, None

See more of: PK/PD Studies
See more of: Poster Abstract Session
<< Previous Abstract | Next Abstract

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.